Table 2.

Trial part 1: adjusted geometric means (Adj. gMean), geometric mean ratios, and 90% confidence intervals (CIs) for the primary pharmacokinetic parameters of digoxin, furosemide, metformin, and rosuvastatin administered as a cocktail with and without the inhibitor verapamil

Endpoint	Test (T)		Reference (R)		Ratio T/R	90% CI	gCVa
	Cocktail + verapamil		Cocktail alone
	N	Adj. gMean	N	Adj. gMean	%	%	%
Digoxin
AUC0–tz (nmol·h/L)	12	13.71	12	13.61	100.70	88.84–114.15	17.9
Cmax (nmol/L)	12	1.42	12	1.17	121.64	100.43–147.33	27.7
Furosemide
AUC0–tz (nmol·h/L)	12	165.80	12	176.85	93.76	86.12–102.06	12.1
Cmax (nmol/L)	12	84.32	12	88.59	95.18	83.03–109.11	19.6
Metformin
AUC0–tz (nmol·h/L)	12	1126.22	12	1357.34	82.97	76.96–89.46	10.7
Cmax (nmol/L)	12	179.45	12	223.78	80.19	73.01–88.08	13.4
Rosuvastatin
AUC0–tz (nmol·h/L)	12	98.98	12	87.29	113.40	97.62–131.72	21.5
Cmax (nmol/L)	12	7.90	12	6.84	115.39	93.80–141.94	30.1

AUC_0–tz area under the plasma concentration–time curve up to the last quantifiable concentration, C_max maximum plasma concentration, gCV geometric coefficient of variation

^aWithin-subject gCV